RenataDHA:RENATA +0.27%83 FCF Margin % is 4.40% as of Mar. 2026, which is 12% above its 10-year median of 3.94. GuruFocus rates DHA:RENATA with a GF Score™ of 83/100 and a GF Value™ of BDT806.73 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 958 Drug Manufacturers companies, Renata ranks worse than 50.31% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Renata's Free Cash Flow for the
three
months ended in Mar. 2026 was BDT501 Mil. Renata's Revenue for the
three
months ended in Mar. 2026 was BDT11,381 Mil. Therefore, Renata's FCF Margin % for the quarter that ended in Mar. 2026 was 4.40%.
The historical rank and industry rank for Renata's FCF Margin % or its related term are showing as below:
DHA:RENATA'
s FCF Margin % Range Over the Past 10 Years
Min: -22.82 Med: 3.94 Max: 14.25
Current: 2.4
During the past 13 years, the highest FCF Margin % of Renata was 14.25%. The lowest was -22.82%. And the median was 3.94%.
DHA:RENATA's FCF Margin % is ranked worse than 50.31% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs DHA:RENATA: 2.40
Renata FCF Margin % Related Terms
Renata FCF Margin % Historical Data
* Premium members only.
The historical data trend for Renata's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:RENATA vs ZTS, UTHR, VTRS: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Renata's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Renata FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Renata's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Renata's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Renata (DHA:RENATA) has a FCF Margin % of 4.40% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Renata and its competitors. This is 12% above median its historical median of 3.94. According to the industry distribution chart, Renata ranks #482 out of 958 companies in the Drug Manufacturers industry, placing it in the top 50.3%.
Is Renata's FCF Margin % too high?
Renata's current FCF Margin % of 4.40% is 12% above median its 10-year median of 3.94. The Drug Manufacturers industry median FCF Margin % is 2.45. Renata's value of 4.40% is 80% above this industry median. Based on the distribution chart, Renata ranks #482 out of 958 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Renata has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Renata's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Renata ranks #482 out of 958 companies for FCF Margin %. This places Renata in the lower half of its industry. The industry median FCF Margin % is 2.45. Renata's value of 4.40% is 80% above this benchmark. While the company's 10-year median is 3.94 vs. the industry median of 2.45, Renata has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Renata's current FCF Margin % of 4.40% is 80% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Renata and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Renata's current FCF Margin % is 4.40%, which is 12% above median its own 10-year median of 3.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renata stock overvalued right now?
Based on GuruFocus' analysis, Renata (DHA:RENATA) is currently considered Significantly Undervalued. The stock's GF Value™ is BDT806.73, compared to a current price of BDT446.30 — trading 44.7% below its estimated fair value. The current FCF Margin % is 4.40%, which is 12% above median its 10-year median of 3.94 and 80% above the Drug Manufacturers industry median of 2.45. Renata's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Renata (DHA:RENATA), the current FCF Margin % is 4.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Renata (DHA:RENATA) Overvalued in 2026?
Based on GuruFocus' analysis, Renata stock appears to be undervalued.
The current stock price of BDT446.30 is trading 44.7% below its estimated GF Value™ of BDT806.73.
GuruFocus considers Renata to be Significantly Undervalued.
Key valuation signals for DHA:RENATA:
FCF Margin %: 4.40% (12% above median its 10-year median of 3.94)
GF Value™: BDT806.73 vs. price of BDT446.30 (44.7% below fair value)
Industry Position: 80% above the Drug Manufacturers median (#482 of 958)
No single metric tells the full story. See the DHA:RENATA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Renata PLC is a Bangladesh based pharmaceutical company. It is engaged in the manufacturing, marketing, and distribution of Human Pharmaceuticals, Animal Health Medicines, Nutritionals, and Vaccines. It manufactures various pharmaceutical products including Beconex Zi Syrup, Cabolin Tablet, Flontin Tablet, Ivana Tablet, and others. Some of the animal health products offered by the company are Doxivet Powder, Fevenil Injection, Diadin Bolus, Renamet Tablet, and others. The company operates in Bangladesh and sells its products locally and internationally.
83GF Score
Get the complete analysis for DHA:RENATA
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:RENATA has been successfully added to your 
